An indirect hemagglutination test has been adapted for use with cytomegalovirus. The test is highly sensitive and reproducible. Both immunoglobulin M and immunoglobulin G antibodies can be detected by this method. The hemagglutination reaction can be inhibited by small amounts of homologous antigen. This principle permits early identification of virus isolated from diagnostic specimens.
The currently available methods for detecting antibody to cytomegalovirus (CMV) have several deficiencies. Some subclasses of immunoglobulin (Ig) G antibody do not fix complement (4) , and IgM antibody is apparently nonreactive in the CMV complement fixation (CF) test (6) . Although the neutralization test (8) is able to detect both IgM and IgG, it is a cumbersome method, and large scale testing is hampered by the slow growth of the virus. Reagents available for performing the indirect IgM fluorescentantibody (FA) test (3) often produce inconsistent results, and the high quality fluorescein-conjugated anti-IgM serum required for the test is both expensive and difficult to obtain (10) . To some extent, these deficiencies hinder research on the epidemiology and natural history of an infection widespread in human populations.
To overcome some of these problems, we have modified a previously described indirect hemagglutination (IHA) test (9, 12) for use with CMV, This paper discusses some of the results obtained with this CMV IHA test and compares them with the results obtained by complement fixation.
MATERIALS AND METHODS
Antigens. A standard CMV antigen was prepared from the AD-169 strain of virus. The same antigen was used for both CF and IHA. The Herpesvirus hominis type 2 antigen (V229) was prepared from a tissue culture isolate in our laboratory. The varicellazoster antigen was obtained commercially (Microbiological Associates, lot 3-4122-GMK).
Tissue culture. Monolayers were prepared with the RU-1 strain of diploid human fetal lung fibroblasts. Eagle's medium as modified by Kissling and Reese (5) and supplemented with 10% fetal calf serum was used for propagation of cells; after growth, 84 the cells were maintained in the modified medium supplemented with 2% fetal calf serum. Antigen preparation. Tissue cultures propagated in 32-oz (ca. 960 ml) prescription bottles were inoculated with 5 X 105 to 10 X 105 TCID5o of the AD-169 strain of CMV. When cytopathic effect (CPE), which consisted of enlarged, rounded, refractile cells, was observed in 80 to 90% of the culture, incubation was continued at 37 C for an additional 24 hr. Each infected monolayer was then rinsed with phosphatebuffered saline (PBS), and the cells were scraped into 2.5 to 5.0 ml of saline buffered at pH 9.0 with 0.05 M glycine-NaOH. The cell suspension was sonically treated for 5 sec at 25W with a Sonifier Cell Disruptor (model W185, Heat Systems-Ultrasonics, Inc., Plainview, N.Y.) with the microtip placed directly in the suspension. It was then clarified by centrifugation at 1,000 X g for 10 min. The antigen was stored in samples at -60 C after the addition of dimethylsulfoxide to a final concentration of 10%. Antigens for IHA inhibition were prepared from tissue culture isolates in culture tubes by rinsing the tubes with PBS, scraping the cells into 0.5 ml of glycine buffer, and sonically treating as above.
Sera. Human sera with both positive and negative CF titers to CMV were tested. These came from the following groups: (i) infants suspected of having congenital infection with CMV, (ii) mothers of these infants, (iii) adults with post-transfusion mononucleosis or heterophile-negative infectious mononucleosis, and (iv) normal, adult blood donors and Center for Disease Control (CDC) personnel.
Human sera from patients with elevated titers and paired sera showing seroconversion to H. hominiis and varicella-zoster were obtained from Bernard Lourie (Virology section, CDC All sera to be tested were diluted 1:10 in rabbit serum diluent, inactivated at 56 C for 30 min, and adsorbed at 4 C for 30 min by using 0.1 ml of 50% washed sheep erythrocytes per milliliter of diluted serum. Twofold dilutions in 0.05-ml volumes were then prepared in plastic microtiter U-plates. To each serum dilution, 0.05 ml of sensitized cells was added.
The plates were sealed with clear tape, shaken, incubated at room temperature for 2 to 4 hr, and then refrigerated until read. Settling patterns were read as positive when the cells were completely and uniformly agglutinated or when a large circle of partially agglutinated cells coated the bottom of the well. Small rings of unagglutinated cells and buttons were read as plus-minus and negative, respectively. The highest serum dilution producing complete or partial agglutination was considered the end point. Controls consisted of (i) a 1:10 dilution of serum plus tanned erythrocytes treated with PBS, (ii) a 1 :10 dilution of serum plus erythrocytes sensitized with uninfected RU-1 tissue culture antigen, and (iii) a positive control consisting of a complete titration of a known CMV-positive serum. IHA-inhibition test. Equal volumes of a positive control serum and a suspension to be tested for CMV antigen were combined in a test tube and allowed to react at room temperature for 60 min. The absorbed serum was then used as indicated for the IHA test, and the test was read for specific inhibition of hemagglutination.
RESULTS
Antigen titration. The 1:8 dilution of CMV antigen was found to be optimal for sensitizing the tanned erythrocytes, both in terms of titer and in clarity of end point ( Table 1 ). The RU-1 control antigen was likewise used at a 1:8 dilution.
Reproducibility. The positive control serum was titrated in every test with a reproducible end point of 1:160. Several sera were tested on multiple occasions and gave results reproducible within one twofold dilution.
In adapting the IHA test for use with CMV, we made no attempt to systematically vary each of the test parameters to determine absolute optimal conditions. Some of the test conditions, however, were found to be critical for the proper performance of the test, and these will be discussed briefly. Some variation was noted in the results obtained with different batches of sheep erythrocytes, primarily in the pattern produced by settled, nonagglutinated cells (and, therefore, in the sharpness of the end point) rather than in actual titer. Cells that were aged for at least 2 weeks gave generally sharper end points than fresh cells. Each new batch of cells was tested with the control serum prior to use. The formulation of the buffers was also found to be extremely important. The pH 7.2 buffer prepared by the method of Stavitsky (12) and having a final Na2HPO4-KH2PO4 buffer concentration of 0.075 M was found to be unsatisfactory in our test system since the cells were spontaneously agglutinated after the sensitization procedure. When this solution was replaced by a 0.01 M Na2HPO4-NaH2PO4 (pH 7.2) buffer, no further problems with spontaneous agglutination occurred.
The rabbit serum diluent was tested by using several serum concentrations. The best settling patterns were produced at dilutions of 1:100 or less. In the absence of serum the cells often failed to form compact buttons, and end points were difficult to read. Once the test conditions were established, the test was easily performed with excellent reproducibility. Sensitivity. Sera from 200 "normal" adult blood donors and CDC personnel were tested by both IHA and CF for CMV antibodies. The comparative titers by the two methods are shown in Fig. 1 . The IHA titers were generally 5 to 10 times higher than the CF titers but showed considerable scatter. All sera in this group found to be negative by CF (<1:8) were also negative by IHA (<1:10), and vice versa. The correlation coefficient for the two tests is 0.48 (omitting the <1:8, <1:10 in performing the calculation).
IHA inhibition. Incubation of a 1:40 dilution of the control serum (titer 1:160) with homologous and heterologous antigen preparations prior to adding sensitized erythrocytes gave the results shown in Table 2 . Homologous antigen in dilutions as high as 1:16 produced complete inhibition of the hemagglutination reaction, whereas heterologous antigen (H. hominis type 2, varicella-zoster, RU-1 cells sonically treated) produced no inhibition, even at a 1:2 dilution.
The inhibition of the specific hemagglutination was extremely sensitive when the positive serum was used at a dilution near its end point (Table 3) Table 4 . A serological rise to any of these agents in an initially CMVnegative individual produced no rise in titer to CMV by either CF or IHA. In one individual with a seroconversion to varicella and a preexisting CMV titer, a boost in titer to CMV was found. In other similar cases, such a boost did not occur.
Infant sera. Table 5 shows the IHA titers in successive sera from infants with declining CF titers, which were thought to indicate passively acquired maternal antibody. The IHA titers followed a pattern similar to the CF but in two cases were still weakly positive at a time when CF antibody could no longer be detected (in infants less than 6 months old). In a group of 12 infants 6 months of age and older, selected on the basis of negative CF titers, no antibody was demonstrable by IHA.
In a series of 14 infants with congenital infection, antibody titers persisted beyond 6 months of age as determined by both CF and IHA. The titers of two of these infants are shown in Table 6 .
Serum fractions. Sera from seven CMV mononucleosis patients and one normal blood donor (no. 5, Although the IHA test generally gave serum titers from 5 to 10 times higher than the CF test (Fig. 1) , few sera have been positive by IHA and negative by CF. It appears that these two tests are essentially equivalent with respect to detection of cases. This may be a reflection of the potency of our CF antigen; an antigen of lower potency might fail to detect antibody by CF at levels that are still detectable by IHA.
The specificity of the IHA test is demonstrated by the IHA-inhibition tests and by the absence of CMV seroconversion accompanying titer rises to related herpesviruses. In one case previously noted, a boost in a pre-existing CMV titer was concomitant with a varicella-zoster seroconversion, but in this patient boosts in titer to H. hominis and vaccinia also occurred. The antigenic relationships among these viruses are at present unclear.
The apparent specificity of the IHA test suggests its use to detect CMV strain differences. Virus isolates could be used either as sensitizing antigens or as inhibiting antigens in the IHAinhibition test. The sensitivity of the IHAinhibition test has allowed us to identify (on an immunological basis) virus isolates from single inoculated tubes several weeks before identification could be made by CF methods. These results suggest that the IHA-inhibition test might be adapted to identify CMV directly from infected urine. 
